Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sarepta Will Challenge Expected No From EMA On Exondys 51

Executive Summary

Sarepta is expecting the European Medicines Agency to recommend against EU approval of its Duchenne muscular dystrophy treatment eteplirsen. Persuading the agency to change its mind during the appeal will be an uphill task for the company.

Advertisement

Related Content

Not The End For Exondys In EU, Says Sarepta
CHMP Preview: Lilly, Merck and Bayer Hopeful On Approvals; Sarepta’s Exondys Appeal Result Due
A Massive First For EU – CAR-T Therapies Kymriah and Yescarta Hoping For CHMP OK
EU Green Light In Sight For Aimovig; 12 Drugs In Line For Potential CHMP Decision
Deal Watch: Genentech Gets Down In The Dirt With Lodo Therapeutics
April CHMP Meeting: Disappointment In Advance For AB Science, Gilead Hopeful On Biktarvy
Zero Success For Companies Appealing Negative CHMP Opinions In EU Last Year

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS123062

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel